Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis

Launched by CHANGHAI HOSPITAL · Jul 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a condition called painless chronic pancreatitis, which is a long-term inflammation of the pancreas that doesn’t cause the usual abdominal pain but can still affect how the pancreas works. The pancreas is important for digestion and blood sugar control, and when it’s damaged, people can develop problems like difficulty digesting food or diabetes. This study aims to find out if certain treatments—called endoscopic therapy and shockwave lithotripsy, which are minimally invasive procedures to clear blockages and stones in the pancreas—can help improve pancreatic function and overall health in people with painless chronic pancreatitis.

Adults between 18 and 85 years old diagnosed with painless chronic pancreatitis who have not had these treatments before may be eligible to join. People with certain complications, other types of pancreatitis, or serious health issues won’t qualify. If you take part, you may receive one or both of these treatments to see if they can protect your pancreas and prevent future problems. The study will also carefully watch for any side effects, including whether these treatments might cause pain to develop. Since research on painless chronic pancreatitis and its treatments is limited, this trial aims to provide clearer answers to help guide better care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 18-85 years.
• • Diagnosed with painless chronic pancreatitis.
• • No prior history of endoscopic retrograde cholangiopancreatography (ERCP) or extracorporeal shockwave lithotripsy (ESWL) treatment.
• Exclusion Criteria:
• • Presence of complications requiring endoscopic or surgical intervention, such as pancreatic pseudocysts, benign biliary strictures, or pancreatic fistulas.
• • Autoimmune pancreatitis.
• • Suspected malignancy.
• • History of pancreatic surgery or gastrointestinal bypass surgery (e.g., Billroth II procedure).
• • End-stage disease.
• • Pregnancy or lactation.
• • Contraindications to ESWL or ERCP.
• • Refusal to provide informed consent.